@nitinjainmd.bsky.social
Professor, Department of Leukemia, MD Anderson Cancer Center
Treatment-free remission in non-transplanted Ph+ #ALL pts is feasible in carefully selected pts. Those in CR1 (n=6) who maintained CMR for >48 mos did not relapse following TKI discontinuation.
@mdanderson.bsky.social
doi.org/10.1002/cncr...
@nitinjainmd.bsky.social @niranjankhaire.bsky.social
In an interview from #ASH24, @nitinjainmd.bsky.social of @mdanderson.bsky.social discusses an analysis assessing the safety of discontinuing TKIs in patients with Ph+ ALL not undergoing alloSCT.
Click here to watch:
👉 https://buff.ly/4hqSeue 👈
#ALLsm #Leusm #Leukemia #HemOnc
As we have increasing Rx options in Firstline #CLL including new updates from #ASH24, here is a summary slide I made for PFS in selected trials by IGHV status
caveat: cross trial comparison but still helpful as we look across trials
#CLL #leusm @MDAndersonNews @ASH_hematology
Great fun last night at Bollywood themed ASH President’s reception
09.12.2024 14:29 — 👍 4 🔁 0 💬 0 📌 0
Ready to get things started at #ASH24! @nitinjainmd.bsky.social
06.12.2024 16:13 — 👍 18 🔁 1 💬 1 📌 0
👉👉👉 #ASH24
TFR (Treatment free remission) is a well established concept in CP CML.
But can you do TFR in Ph+ ALL in CR1 among pts who don’t undergo allo-SCT?
👉14 pt retrospective series at #ASH24
Please see us at the poster on Saturday in San Diego.
Work led by Drs Kugler and Khaire
Stargazing in Joshua Tree National Park on Thanksgiving night
29.11.2024 15:30 — 👍 5 🔁 0 💬 0 📌 0
How was your weekend??!!
25.11.2024 03:39 — 👍 5 🔁 0 💬 0 📌 0I am on it!
25.11.2024 01:30 — 👍 1 🔁 0 💬 1 📌 0
